Regeneron Phase 2 COURAGE Trial: Trevogrumab and Lean Mass Preservation
On October 1 2026 Regeneron announced results from its Phase 2 COURAGE trial showing that the investigational antibody trevogrumab preserved lean mass alongside semaglutide. The company reported that the findings were presented at the European Association for the Study of Diabetes Annual Meeting and are in press with The Lancet.
Investigating Tissue Loss During Weight Reduction
The COURAGE trial evaluated the investigational drug trevogrumab alongside a 2.4 mg dose of semaglutide over a period of 52 weeks. Trevogrumab functions as an anti-GDF8 or anti-myostatin antibody designed to target muscle regulation pathways. The study focused specifically on individuals diagnosed with obesity to track their physiological changes during active weight reduction. A secondary report indicated the trial involved nearly 1000 people aged 18 to 65.
The lower-dose portion of the trial compared semaglutide alone against semaglutide paired with trevogrumab at either 25 mg or 75 mg. Regeneron designed the study to observe alterations in body composition rather than total scale weight reductions. Understanding how these medications impact body composition remains a critical focus for men managing their long-term physical capacity. The researchers utilized dual-energy X-ray absorptiometry to track lean mass changes precisely throughout the year.
The researchers also included a predefined magnetic resonance imaging substudy within the broader trial parameters. This specific component assessed thigh fat-free muscle volume to provide a different measurement of tissue retention. The trial structure allowed investigators to evaluate tissue changes at both the 26-week midpoint and the 52-week conclusion. Collecting data at multiple time points helped researchers observe how the tissue preservation rates shifted over a full twelve months.
Lean Mass and Muscle Volume Results
The clinical data revealed distinct differences in lean mass retention between the various treatment groups at the conclusion of the trial. At week 52 participants taking semaglutide plus a placebo experienced a 7.3 percent decline in their DXA-measured lean mass. Those receiving semaglutide paired with 25 mg of trevogrumab saw a 5.8 percent decline over the same period. The group taking 75 mg of the investigational antibody recorded a 4.2 percent drop in lean mass.
Regeneron calculated that the 25 mg and 75 mg doses resulted in 20.5 percent and 42.5 percent less lean-mass loss respectively compared to semaglutide plus placebo. The trial also captured significant data at the 26-week mark. At that midpoint lean mass had declined by 6.7 percent with semaglutide alone. The mid-year decline was 4.7 percent for the 25 mg group and 3.3 percent for the 75 mg group.
The company reported 29.9 percent and 50.7 percent relative lean-mass preservation for the two trevogrumab doses at the 26-week mark. The MRI substudy provided additional data specifically regarding thigh fat-free muscle volume. At week 52 the 25 mg dose showed a 71.8 percent relative preservation compared to semaglutide plus placebo. The 75 mg dose demonstrated a 68.9 percent relative preservation in that same evaluable MRI group.
Regeneron clarified that adding trevogrumab did not meaningfully increase total weight loss beyond what semaglutide achieved alone. The company reported that participants tolerated the lower-dose trevogrumab treatment well. At least one adverse event was reported in 77 percent of participants receiving the investigational drug. The placebo group reported an adverse event rate of 82 percent over the same period.
The most common adverse events included nausea, constipation, diarrhea and vomiting. Each of those specific adverse events occurred in at least 10 percent of the patients involved. Managing gastrointestinal tolerance is a known factor when utilizing GLP-1 receptor agonists for weight reduction. The addition of the anti-myostatin antibody did not appear to elevate the overall frequency of these common side effects.
Trial Limitations and Clinical Context
Regeneron clearly stated that regulators have not evaluated the safety and efficacy of trevogrumab. The drug remains strictly an investigational product candidate rather than a currently available clinical option. The press release omitted several key data points. The company did not provide the full trial report or overall sample sizes. They also excluded numerical weight-loss results and detailed statistical analyses. Furthermore they did not publish quantified results for the low-lean-mass subgroup.
The strongest relative lean-mass preservation occurred with the 75 mg dose at week 26, but that preservation rate was lower at week 52. The 25 mg arm displayed a completely different pattern across those two specific time points. This variation indicates a development-stage trial signal rather than a uniform medical benefit. Readers must distinguish this company-released topline detail from a complete peer-reviewed account.
The measurements used in the COURAGE trial track tissue volume rather than physical capability. Lean mass measurements and MRI thigh muscle volume do not automatically translate to usable physical strength. The reported results do not establish that participants gained strength, improved their mobility or reduced their risk of falls. Evaluating muscle mass versus usable strength remains necessary before drawing conclusions about everyday independence.
For men concerned about preserving strength while losing weight the defensible takeaway is to discuss physical function with a clinician. Patients should not assume that a drug preserving a DXA or MRI measure has already been shown to preserve everyday capability. The trial results do not establish a specific exercise or medical treatment protocol. Treatment decisions ultimately belong with the prescribing clinician.
Julio Rosenstock is the lead principal investigator for the COURAGE trial and a clinical professor of medicine at the University of Texas Southwestern Medical Center. He stated the trial showed the drug could preserve lean mass during weight loss and that MRI measurements supported the findings. This reflects the interpretation of the investigator rather than a new clinical recommendation. The findings are reportedly in press with The Lancet.
Future Research in Older Populations
Regeneron senior vice president Boaz Hirshberg addressed the specific challenge of muscle retention in older populations. He stated that muscle loss during GLP-1 weight-loss treatment is a concern for older adults and people facing sarcopenia or frailty. Hirshberg characterized the clinical goal as improving the quality of the weight lost rather than just the quantity. Preserving physical capability requires strategies for retaining strength and power throughout the aging process.
To address these specific demographic concerns Regeneron plans a subsequent Phase 2 study. That future trial will test trevogrumab with GLP-1 therapies specifically in older adults with obesity and decreased muscle mass or strength. The company also noted a preliminary observation regarding participants who began the current study with low lean mass. Those individuals experienced greater lean-mass loss with semaglutide alone and numerically more preservation when the investigational drug was added.
While this research confirms that combination therapies can alter the physiological composition of weight loss, it does not currently alter established clinical best practices for maintaining strength.
How Everfitguys helps
Evaluating the true functional benefit of new muscle-preserving drugs requires mature men to look beyond preliminary imaging data and single-year clinical trials. Confusion about hormonal changes and testosterone claims often complicates a man's attempt to understand his changing body composition, but Everfitguys translates this complex evidence so he can make grounded decisions about his long-term capability.
Sources
Stay sharp
Get stories
The best writing on craft and life, delivered once a week. No noise, just the good stuff.
